/

Empresas

La

No verificado

Lantern Pharma

Sobre qué escribimos

BiotecnologíaEventosFarmacéuticaIndustriaOncología

3 Comunicados de prensa

Ver todos los comunicados de prensa

07/08/2024

Oncología

Salud

Medicina - Varios

Sanidad

Farmacéutica

Biotecnología

Eventos

Industria

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Fuente

Editor

1.00

0

05/08/2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Fuente

Editor

1.00

0

10/07/2024

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0